Skip to main content
. 2024 Aug 30;15:1399983. doi: 10.3389/fneur.2024.1399983

Table 2.

The value of various clinical factors and MRI morphologic features in predicting the intracranial therapeutic efficacy of the second-line osimertinib treatment.

A. Univariate logistic regression OR 95% CI OR p-value
Age: >60 vs. ≤60 Y 4.06 1.64–10.05 0.002
Sex: Male vs. Female 0.77 0.34–1.75 0.539
Smoking history: Yes vs. No 0.85 0.25–2.88 0.792
ECOG-PS score: ≥1 vs. 0 0.86 0.40–1.83 0.692
Initial EGFR mutation: 19Del vs. L858R 0.74 0.32–1.70 0.473
Initial EGFR mutation: Others vs. L858R 0.43 0.08–2.21 0.314
First-line EGFR-TKI: Erlotinib vs. Gefitinib 0.48 0.14–1.64 0.245
First-line EGFR-TKI: Icotinib vs. Gefitinib 0.53 0.20–1.43 0.209
First-line EGFR-TKI: Afatinib vs. Gefitinib 0.91 0.08–10.6 0.939
First-line EGFR-TKI PFS: ≥12 Mo vs. <12 Mo 1.83 0.81–4.14 0.148
T stage: T3-4 vs. T1-2 0.90 0.39–2.06 0.805
N stage: N0-1 vs. N2-3 1.17 0.48–2.87 0.733
M stage: M1c vs. M1b 0.38 0.10–1.42 0.150
Stage: IVb vs. IVa 0.38 0.10–1.42 0.150
Maximum diameter of BM: >2 cm vs. ≤2 cm 1.57 0.48–5.21 0.465
Ring enhancement: Yes vs. No 2.53 1.12–5.75 0.026
Peritumor edema: Yes vs. No 4.72 1.95–11.45 0.001
Location of BM: Frontal lobe vs. Parietal lobe 4.67 0.89–24.35 0.068
Location of BM: Occipital lobe vs. Parietal lobe 2.40 0.41–14.11 0.333
Location of BM: Temporal lobe vs. Parietal lobe 4.67 0.78–28.05 0.092
Location of BM: Cerebellum vs. Parietal lobe 0.40 0.03–4.96 0.476
Location of BM: Others vs. Parietal lobe 2.00 0.31–13.06 0.469
B. Multivariate logistic regression OR 95% CI OR p-value
Age: >60 vs. ≤60 Y 4.23 1.61–11.25 0.003
Ring enhancement: Yes vs. No 2.337 0.92–5.94 0.074
Peritumor edema: Yes vs. No 3.80 1.48–9.77 0.006
*

Stepwise regression method, exclusion criteria for variables: p < 0.1.

NSCLC, Non-Small Cell Lung Cancer; ECOG-PS, Eastern Cooperative Oncology Group performance score; EGFR, Epidermal Growth Factor Receptor; TKI, Tyrosine Kinase Inhibitor; PFS, Progression-free survival; BM, brain metastases.